IMUNON Advances IMNN-001 Phase 2 After Favorable Safety Review
LAWRENCEVILLE, N.J. — September 22, 2026 IMUNON announced that the Independent Data Monitoring Committee (IDMC) overseeing its Phase 2...
bevacizumab
Advertisement
Aveva Clears Patent Appeal for Generic ZTlido Launch
Miramar, Florida, August 5, 2026 Aveva Drug Delivery Systems, Inc., a DifGen Pharmaceuticals company, has secured a significant legal...
Innovent Advances IBI363 Into Phase III Colorectal Cancer Trial
San Francisco, USA and Suzhou, China, August 6, 2026 Innovent Biologics has completed dosing of the first patient in...
Leads Biolabs Advances Opamtistomig Phase II Trial in First-Line Liver Cancer
NANJING, China, August 6, 2026 Leads Biolabs announced that its Phase II clinical study evaluating Opamtistomig (LBL-024) in combination...
Oncolytics Advances REO 033 Development
SAN DIEGO, July 13, 2026 Oncolytics Biotech announced a significant clinical and regulatory update for its REO 033 randomized...
Advertisements
Lupin Launches Azilsartan Medoxomil Tablets in U.S. Market
MUMBAI, India & NAPLES, Fla., June 17, 2026 Lupin Limited, a leading global pharmaceutical company, has announced the launch...
TORL BioTherapeutics Reports Promising Ovarian Cancer Data
LOS ANGELES, Calif., June 18, 2026 TORL BioTherapeutics has reported encouraging preliminary Phase 1 clinical data for its investigational...
Cardiff Oncology Showcases Promising Phase 2 Onvansertib Results Ahead of ASCO 2026
SAN DIEGO, Calif., May 21, 2026 Cardiff Oncology, Inc. announced that updated data from its ongoing Phase 2 CRDF-004...
Rznomics RZ-001 Shows Strong HCC Clinical Data AACR
SAN DIEGO, Calif., April 19, 2026 Rznomics Inc. announced encouraging interim clinical results from its ongoing study of RZ-001,...
Advertisement
